Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
2.810
-0.120 (-4.10%)
At close: May 18, 2026, 4:00 PM EDT
2.874
+0.064 (2.27%)
Pre-market: May 19, 2026, 8:40 AM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Prime Medicine stock has a consensus rating of "Buy" and an average price target of $6.92. The average 1-year stock price forecast is 146.26% higher than the current stock price, while the lowest is $4.25 (+51.25%) and the highest is $11 (+291.46%).
Price Target: $6.92 (+146.26%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 12, 2026.
Analyst Ratings
The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $11 | Buy | Initiates | $11 | +291.46% | Mar 12, 2026 |
| Citigroup | Citigroup | Hold Maintains $5 → $4.25 | Hold | Maintains | $5 → $4.25 | +51.25% | Nov 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +220.28% | Nov 10, 2025 |
| Citigroup | Citigroup | Hold Maintains $1.5 → $4 | Hold | Maintains | $1.5 → $4 | +42.35% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +255.87% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
4.96M
from 4.63M
Increased by 7.06%
Revenue Next Year
7.29M
from 4.96M
Increased by 47.01%
EPS This Year
-0.96
from -1.35
EPS Next Year
-0.91
from -0.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.5M | 23.1M | ||||||
| Avg | 5.0M | 7.3M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 126.7% | 365.8% | ||||||
| Avg | 7.1% | 47.0% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.72 | -0.45 | ||||||
| Avg | -0.96 | -0.91 | ||||||
| Low | -1.16 | -1.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.